Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.35 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13341595 | 0.87 | ADORA2A (0.47) | ADORA2AKMT2AADORA1TP53MAPT | |
| SCHEMBL8217497 | 0.85 | ADORA2A (0.49) | ADORA2AKMT2AADORA1MAPT | |
| SCHEMBL8224060 | 0.84 | ADORA2A (0.45) | ADORA2AADORA1MAPT | |
| SCHEMBL8224064 | 0.83 | ADORA2A (0.49) | ADORA2AKMT2AADORA1PTGER4TRAP1 | |
| SCHEMBL8221012 | 0.82 | ADORA2A (0.46) | ADORA2AADORA1HSP90B1TRAP1 | |
| SCHEMBL8221845 | 0.81 | ADORA2A (0.55) | ADORA2AADORA1 | |
| SCHEMBL8220814 | 0.81 | ADORA2A (0.46) | ADORA2AADORA1 | |
| SCHEMBL8221822 | 0.81 | ADORA2A (0.63) | ADORA2AADORA1 | |
| SCHEMBL8224740 | 0.80 | TNF (0.51) | ADORA2AKMT2AADORA1MAPT | |
| SCHEMBL8217493 | 0.80 | ADORA2A (0.54) | ADORA2AADORA1TP53PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713985-B2 | Adenosine Aa2 receptor antagonists | SCHERING CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713985-B2 | Adenosine Aa2 receptor antagonists | SCHERING CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2038285-B1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2008-10-16 | — | — | US | disclosed |
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2008-10-16 | — | — | US | disclosed |
| WO-2008002596-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885KMT2A 3780/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.